Compare · LUCY vs STAA
LUCY vs STAA
Side-by-side comparison of Innovative Eyewear Inc. (LUCY) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUCY and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- STAA is the larger of the two at $1.28B, about 190.8x LUCY ($6.7M).
- LUCY has been more active in the news (9 items in the past 4 weeks vs 6 for STAA).
- STAA has more recent analyst coverage (25 ratings vs 0 for LUCY).
- Company
- Innovative Eyewear Inc.
- STAAR Surgical Company
- Price
- -
- -
- Market cap
- $6.7M
- $1.28B
- 1M return
- -
- +13.83%
- 1Y return
- -
- -1.34%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 9
- 6
- Recent ratings
- 0
- 25
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest LUCY
- Innovative Eyewear Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by Innovative Eyewear Inc.
- SEC Form 10-Q filed by Innovative Eyewear Inc.
- Innovative Eyewear Reports Third-Quarter 2026 Results
- Chief Financial Officer Gayle Oswald was granted 60,000 shares, increasing direct ownership by 303% to 79,798 units (SEC Form 4)
- Chief AI & Growth Officer Dabrowski Konrad was granted 50,000 shares, increasing direct ownership by 122% to 90,977 units (SEC Form 4)
- Chief Operating Officer Abondano Joaquin was granted 90,000 shares, increasing direct ownership by 360% to 115,012 units (SEC Form 4)
- Chief Executive Officer Gross Harrison R. was granted 100,000 shares, increasing direct ownership by 284% to 135,195 units (SEC Form 4)
- Chief Technology Officer Cohen David Eric was granted 60,000 shares, increasing direct ownership by 254% to 83,622 units (SEC Form 4)
- Innovative Eyewear, Inc. Receives Time Magazine's Best Inventions of 2026 Award
Latest STAA
- Amendment: SEC Form SCHEDULE 13G/A filed by STAAR Surgical Company
- SEC Form 10-Q filed by STAAR Surgical Company
- STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical Reports Third Quarter 2026 Results
- STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific
- STAAR Surgical to Participate in Upcoming Investor Conferences
- STAAR Surgical to Host Third Quarter 2026 Earnings Results Call and Webcast on November 4, 2026
- STAAR Surgical Names Andrew Pilon as Vice President of Business Development
- Amendment: STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical upgraded by Stifel with a new price target